Top

Published in:

01-11-2009 | Basic Neurosciences, Genetics and Immunology - Review Article

The particular relationship between Parkinson’s disease and malignancy: a focus on skin cancers

Authors: Rivka Inzelberg, Simon D. Israeli-Korn

Published in: Journal of Neural Transmission | Issue 11/2009

Abstract

Although the risk for most cancers appears to be relatively low in patients with Parkinson’s disease (PD), skin cancers and melanomas occur more frequently in the PD population as compared to controls. This article summarizes the findings of cohort studies on skin cancer in Parkinson’s disease. Given that melanoma may precede use of l-dopa, the increased risk of melanoma for PD patients cannot be attributed to l-dopa. On the basis of these observations it may be reasonable to recommend that all patients with PD, whether treated with l-dopa or not, should undergo regular dermatological screening for neoplastic or pre-neoplastic skin lesions, especially melanoma.

Baade PD, Fritschi L, Freedman DM (2007) Mortality due to amyotrophic lateral sclerosis and Parkinson’s disease among melanoma patients. Neuroepidemiology 28:16–20CrossRefPubMed

Ben-Shlomo Y, Marmot MG (1995) Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 58:293–299CrossRefPubMed

Bertoni JM, Arlette JP, Fernandez HH, Frei K, Gordon M, Hassan M (2006) Epidemiologic association of Parkinson’s disease and melanoma. Mov Disord 21(Suppl 15):S610

Chakroborty D, Chowdhury UR, Sarkar C, Baral R, Dasgupta PS, Basu S (2008) Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization. J Clin Invest 118:1380–1389CrossRefPubMed

Constantinescu R, Romer M, Kieburtz K (2007) Malignant melanoma in early Parkinson’s disease: the DATATOP trial. Mov Disord 22:720–722CrossRefPubMed

D’Amelio M, Ragonese P, Sconzo G, Aridon P, Savettieri G (2009) Parkinson’s disease and cancer: insights for pathogenesis from epidemiology. Ann N Y Acad Sci 1155:324–334CrossRefPubMed

Deng H, Le W, Guo Y, Hunter CB, Xie W, Huang M, Jankovic J (2006) Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J Neurol Sci 251:102–106CrossRefPubMed

Doshay LJ (1954) Problem situations in paralysis agitans. JAMA 156:680–683

Driver JA, Logroscino G, Buring JE, Gaziano JM, Kurth T (2007a) A prospective cohort study of cancer incidence following the diagnosis of Parkinson’s disease. Cancer Epidemiol Biomarkers Prev 16:1260–1265CrossRefPubMed

Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G (2007b) Prospective case–control study of nonfatal cancer preceding the diagnosis of Parkinson’s disease. Cancer Causes Control 18:705–711CrossRefPubMed

Elbaz A, Peterson BJ, Yang P, Van Gerpen JAV, Bower JH, Maraganore DM, McDonnell SK, Ahlkog JE, Rocca WA (2002) Nonfatal cancer preceding Parkinson’s disease. Epidemiology 13:157–164CrossRefPubMed

Elbaz A, Peterson BJ, Bower JH, Yang P, Maraganore DM, McDonnell SK (2005) Risk of cancer after the diagnosis of Parkinson’s disease: a historical cohort. Mov Disord 30:719–725CrossRef

Ferreira J, Silva JM, Freire R, Pignatelli J, Guedes LC, Feijó A, Rosa MM, Coelho M, Costa J, Noronha A, Hewett R, Gomes AM, Cirne de Castro JL, Rascol O, Sampaio C (2007) Skin cancers and precancerous lesions in Parkinson’s Disease patients. Mov Disord 22:1471–1475CrossRefPubMed

Fiala KH, Whetteckey J, Manyam BV (2003) Malignant melanoma and levodopa in Parkinson’s disease: causality or coincidence? Parkinsonism Relat Disord 9:321–327CrossRefPubMed

Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A (2009) Genetic determinants of hair color and Parkinson’s disease risk. Ann Neurol 65:76–82CrossRefPubMed

Gorrell JM, Johnson CC, Rybicki BA (1994) PD and its comorbid disorders. Neurology 44:1865–1868

Gurney H, Coates A, Kefford R (1991) The use of l-dopa and carbidopa in metastatic malignant melanoma. J Invest Dermatol 96:85–87CrossRefPubMed

Haider SA, Thaller VT (1992) Lid melanoma and parkinsonism. Br J Ophthalmol 76:246–247CrossRefPubMed

Harada H, Nishikawa S, Takahashi K (1983) Epidemiology of Parkinson’s disease in a Japanese city. Arch Neurol 40:151–154PubMed

Hassin-Baer S, Laitman Y, Azizi E, Molchadski I, Galore-Haskel G, Barak F, Cohen OS, Friedman E (2009) The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel. J Neurol 256:483–487CrossRefPubMed

Herrero Hernández E (2009) Pigmentation as a clue to understanding Parkinson’s disease and melanoma. Ann Neurol 65:759CrossRefPubMed

Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442PubMed

Inzelberg R, Jankovic J (2007) Are Parkinson disease patients protected from some but not all cancers? Neurology 69:1542–1550CrossRefPubMed

Inzelberg R, Jankovic J (2008) Are Parkinson disease patients protected from some but not all cancers? Neurology 71:1650–1651CrossRef

Inzelberg R, Rabey JM, Djaldetti R, Reches A, Badarny S, Hassin-Baer S, Trau H, Aharon-Peretz J, Huberman M, Gilead L, Giladi N (2007) Elevated prevalence of malignant melanoma in Israeli patients with Parkinson’s disease. Mov Disord 22(Suppl 16):S169–S170

Jansson B, Jankovic J (1985) Low cancer rates among patients with Parkinson’s disease. Ann Neurol 17:505–509CrossRefPubMed

Kincannon J, Boutzale C (1999) The physiology of pigmented nevi. Pediatrics 104:1042–1045PubMed

Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S (2000) Mortality and cancer in Parkinson’s disease. J Neurol 247:429–434CrossRefPubMed

Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH (1995) Occurrence of different cancers in Parkinson’s disease. Br Med J 310:1500–1501

Olsen JH (1997) Avoidable cancers in the Nordic countries. Aims and background. APMIS Suppl 76:1–8PubMed

Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H (2005) Atypical cancer pattern in patients with Parkinson’s disease. Br J Cancer 92:201–205CrossRefPubMed

Olsen JH, Friis S, Frederiksen K (2006) Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 17:582–587CrossRefPubMed

Olsen JH, Tangerud K, Wermuth L, Frederiksen K, Friis S (2007) Treatment with levodopa and risk for malignant melanoma. Mov Disord 22:1252–1257CrossRefPubMed

Pfutzner W, Przybilla B (1997) Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature. J Am Acad Dermatol 37:332–336CrossRefPubMed

Pritchard PB III, Netsky MG (1973) Prevalence of neoplasms and causes of death in paralysis agitans. A necropsy study. Neurology 23:215–222PubMed

Rampen FH (1985) Levodopa and melanoma: three cases and review of literature. J Neurol Neurosurg Psychiatry 48:585–588CrossRefPubMed

Rigel DS, Patel Z, Bolognia J, Eichler C, Ellis DL, Friedman RJ (2006) Evaluation of Parkinson’s disease (PD) prevalence in patients with malignant melanoma. Mov Disord 21(suppl 13):S58

Sandyk R (1992) Accelerated growth of malignant melanoma by levodopa in Parkinson’s disease and role of the pineal gland. Int J Neurosci 63:137–140PubMedCrossRef

Sarkar C, Chakroborty D, Chowdhury UR, Dasgupta PS, Basu S (2008) Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin Cancer Res 14:2502–2510CrossRefPubMed

Siple JF, Schneider DC, Wanlass WA, Rosenblatt BK (2000) Levodopa therapy and the risk of malignant melanoma. Ann Pharmacother 34:382–385CrossRefPubMed

Skibba JL, Pinckley J, Gilbert EF, Johnson RO (1972) Multiple primary melanoma following administration of levodopa. Arch Pathol 93:556–561PubMed

Sober AJ, Wick MM (1978) Levodopa therapy and malignant melanoma. JAMA 240:554–555CrossRefPubMed

Strongosky AJ, Farrer M, Wszolek ZK (2008) Are Parkinson disease patients protected from some but not all cancers? Neurology 71:1650CrossRefPubMed

Tomiyama H, Li Y, Funayama M, Hasegawa K, Yoshino H, Kubo S, Sato K, Hattori T, Lu CS, Inzelberg R, Djaldetti R, Melamed E, Amouri R, Gouider-Khouja N, Hentati F, Hatano Y, Wang M, Imamichi Y, Mizoguchi K, Miyajima H, Obata F, Toda T, Farrer MJ, Mizuno Y, Hattori N (2006) Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson’s disease patients from 18 countries. Mov Disord 21:1102–1108CrossRefPubMed

Vanacore N, Spila-Alegiani S, Raschetti R, Meco G (1999) Mortality cancer risk in parkinsonian patients: a population-based study. Neurology 52:395–398PubMed

Westlund K, Hougen A (1956) Cancer as a cause of death among patients with other chronic diseases. JAMA 162:1003–1008

Zanetti R, Rosso S (2007) Levodopa and the risk of melanoma. Lancet 369:9558

Zanetti R, Loria D, Rosso S (2006) Melanoma, Parkinson’s disease and levodopa: causal or spurious link? A review of the literature. Melanoma Res 16:201–206CrossRefPubMed

Title: The particular relationship between Parkinson’s disease and malignancy: a focus on skin cancers
Authors: Rivka Inzelberg
Simon D. Israeli-Korn
Publication date: 01-11-2009
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 11/2009
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-009-0322-x

At a glance: The STEP trials

Springer Medicine

The particular relationship between Parkinson’s disease and malignancy: a focus on skin cancers

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2009

NAP protects against cyanide-related microtubule destruction

ApoE4-dependent Aβ-mediated neurodegeneration is associated with inflammatory activation in the hippocampus but not the septum

Prediction of Alzheimer dementia with short neuropsychological instruments

Editorial

Pro-apoptotic protein–protein interactions of the extended N-AChE terminus

Association analysis of Rgs7 variants with panic disorder